top of page

CanCURE

The Canadian HIV Cure Enterprise (CanCURE) is a research collaboratory focused on studying HIV persistence during antiretroviral therapy and developing strategies towards a sustainable HIV remission. Our innovative scientific program is supported by the Canadian Institutes of Health Research (CIHR).

CanCURE Photo Gallery

​

Available Positions

Research Assistant or Associate

Available at the Research Institute of McGill University Health Centre (RI-MUHC) to work on CIHR-funded research studies on HIV immunology. The candidate will be supervised by Dr Cecilia Costiniuk, Associate Professor in Infectious Diseases at McGill.

​

Postdoctoral Fellow 

Available at the Research Institute of McGill University Health Centre (RI-MUHC) to work on CIHR-funded research studies on HIV immunology. The candidate will be supervised by Dr Cecilia Costiniuk, Associate Professor in Infectious Diseases at McGill.

 

                          Postdoctoral Fellow

Human Immunodeficiency Virus (HIV)-host interactions governing HIV persistence in different models of humanized mice. Dr. Eric Cohen, Montreal Clinical Research Institute (IRCM, Montreal)

Research Assistant or Associate

Department of Biological Sciences, Université du Québec à Montréal (UQAM), Canada Research Chair in Immuno-virology, Dr Jenabian 

Postdoctoral Fellow 

Laboratory of Dr Mohammad-Ali Jenabian, the holder of the Canada research chair in Immuno-Virology, at the Department of Biological Sciences, University of Quebec at Montreal (UQAM) 

​

​

Community Advisory Board

CanCURE Advisory Board-Call for new members. Seeking nominations from community members to fill several positions on the advisory board. CanCURE strives to be representative of Canada’s geographic regions as well as Canadian populations most affected by HIV and related health conditions.

​

Publications

Gantner et al. HIV rapidly targets a diverse pool of CD4+ T cells to
establish productive and latent infections. Immunity. March 2023

​

Colas et al. Generation of functional human T cell development in NOD/SCID/IL2rγnull humanized mice without using fetal tissue: Application as a model of HIV infection and persistence. Stem Cell Reports. February 2023

​

Fert et al. Targeting Th17 cells in HIV-1 remission / cure interventions. Trends in Immunology. July 2022

​

Tremblay et al. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in
Human Primary Macrophages. Journal of Virology. February 2022

​

Murooka et al. T cell migration potentiates HIV infection by
enhancing viral fusion and integration. Cell Reports. February 2022

​

Salinas et al. Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. PNAS. November 2021

​

Planas et al. Peculiar Phenotypic and Cytotoxic Features of Pulmonary Mucosal CD8 T Cells in People Living with HIV Receiving Long-Term Antiretroviral Therapy. EBioMedicine. March 2021​​

​

Routy et al. Beyond the Absence of CD4 T-Cell Count: A Novel Genetic CD4 T-Cell Deficiency Disorder With a Contingency Plan. J Infect Dis. February 2021

​

Peng et al. Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis. J Virus Erad.​ February 2021

​

Abdel-Mohsen et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Med. September 2020 

​

Gantner et al. Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. Nature Communications. August 2020

bottom of page